Clinical Trial Update: Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of ORM-5029 in HER2-expressing advanced solid tumors, including HER2-positive breast cancer, was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ORM-5029

Snippet

Sponsor: Orum Therapeutics USA, Inc. | Conditions: HER2-positive Breast Cancer, HER-2 Protein Overexpression | Phase 1 | Status: TERMINATED